Ovarian cancer is the leading cause of death among patients with gynaecological cancers with a 5 year survival rate, averaged over all stages, of 29-32% (Scully, 1987) . Such high mortality is due largely to the insidious early progression of the disease and consequent detection at an advanced tumour stage. The absence of a sufficiently specific and sensitive screening test for diagnosis or prognosis of the disease compounds the problem of its treatment.
Progesterone receptor estimation yields prognostic information in ovarian carcinoma (Slotman et al., 1990; Chadha et al., 1993; Noguchi et al., 1993) , indicating a positive relationship between progesterone receptor expression and prognosis. The cDNA for the human progesterone receptor (hPR) was first cloned and sequenced by Misrahi et al. (1987) and later by Kastner et al. (1990) . The structure of the hPR gene has recently been described (Figure la) (Misrahi et al., 1993) . The presence of multiple forms of the hPR in ovarian carcinoma has been reported (Scharl et al., 1991) . Loss of heterozygosity at the 1q23 locus in ovarian carcinoma has been reported (Foulkes et al., 1993) , indicating the presence in this region of a tumour-suppressor gene relevant to ovarian carcinoma. The hPR gene has been mapped by separate groups to the 1 lq22-q23 locus (Rousseau-Merck et al., 1987; Mattei et al., 1988) . Transfection of an ovarian carcinoma cell line with chromosome 11 has resulted in suppression of growth (Cao et al., 1993) , further suggestive of the presence of tumoursuppressive regions on this chromosome.
Restriction fragment length polymorphisms (RFLPs) are somatic or hereditary variations in the length of a DNA fragment yielded by specific restriction endonuclease digestion. Steroid hormone receptor gene RFLPs have been previously studied in human female malignancies. A HindII polymorphism in the progesterone receptor gene exhibited non-Mendelian distribution in primary breast tumours (Fuqua et al., 1991) . A HindII polymorphism of the oestrogen receptor gene was found to correlate with progesterone receptor expression in primary breast tumours (Wanless et al., 1991) . Furthermore, a specific pattern of differential expression of the chicken ovalbumin upstream promoter transcription factor (COUP-TF), an orphan of the steroid hormone receptor superfamily, has been identified in human ovarian cancer cell lines (Kieback et al., 1993) , indicating the possible role of this novel steroid receptor in ovarian carcinoma.
The TaqI restriction endonuclease recognition site TCGA, containing all four base pairs found in DNA, allows analysis of all 12 potential single base pair mutations (Sandy et al., 1992) . The presence in this recognition site of the dinucleotide sequence CpG is of particular importance given that deamination of cytosine or 5-methylcytosine in CpG dinucleotides is a common mechanism for the formation of C to T transitions in cancer-related genes (Hollstein et al., 1991) . For these reasons, TaqI is especially useful in discerning polymorphic alleles by RFLP analysis.
In order to investigate the status of the hPR gene in primary ovarian carcinoma, we analysed peripheral leucocyte genomic DNA from ovarian carcinoma patients and controls for appearance of a germline TaqI RFLP in the hPR gene.
Material and methods
Polymerase chain reaction (PCR) and hPR cDNA region-specific probes Refer to Figure 1 . Screening of a Agtl 1 random-primed T47D human breast cancer cell line cDNA library with a 2 kb chick oviduct progesterone receptor cDNA (both gifts from Dr BW O'Malley, Baylor College of Medicine, Houston, TX, USA) yielded a 1.85 kb cDNA, hPR-1, which was subsequently cloned in pGEM-4 (Promega, Madison, WI, USA) using EcoRI to yield pGEM-4-hPR-I (Clifford-Brougham, 1989) . The hPR-l cDNA ( Figure Ib) consists of 1846 base pairs (bp), of which 1084 bp represent 3' coding sequence and the remaining 762 bp is 3'-untranslated sequence. hPR-l probe was prepared for Southern analysis by digestion of pGEM4-hPR-1 with EcoRI (Boehringer Mannheim), under conditions specified by the manufacturer, and purified twice by electroelution after separation on a 1% agarose electrophoresis gel. The hPR-2 cDNA probe ( Figure 1c ) was generated by PCR using sense primer no. 1 (Figure 2 , lanes 1 and 2); 2.7 kb/i.9 kb, individuals heterozygous for the TI and T2 alleles (Figure 2, lane 3) ; and 1.9 kb/i.9 kb individuals homozygous for the T2 allele ( Figure 3 , lanes 1 and 2).
Localisation of aditional TaqI restriction site hPR cDNA region specific probes were used for a preliminary localisation of the additional TaqI site in the hPR gene. Figure 2 shows three TaqI-digested genomic DNA samples probed with the hPR-1 cDNA probe (Figure lb) .
The restriction fragment hybridisation pattern shows four invariant bands at approximately 5.0, 4.2, 3.5 and 0.6 kb and the two variant fragments at 2.7 kb and 1.9 kb. Figure 3 shows the autoradiographic pattern when the hPR-2 cDNA probe ( Figure Ic) Kastner et al. (1990) in the human progesterone receptor cDNA (Figure 1 ).
Allelic distribution andfrequency in ovarian cancer patients and controls
Significant differences in the distribution of TI and T2 alleles were observed between the pooled German/Irish ovarian carcinoma cases and in the pooled controls (P<0.025) ( Table  I) . No significant difference could be demonstrated in the distribution of the alleles between cases and controls in Ireland (P = 0.18). The frequency of the T2 allele could not be shown to differ significantly (P>0.4) between the case groups of both countries, but was significantly higher in the Irish control group than in the German control group Fugwe 3 Representative autoradiographic pattern using the hPR-2 cDNA fragment to probe TaqI-digested genomic DNA. Three genotypes are evident: 2.7 kb/1.9 kb, individuals heterozygous for the TI and T2 alleles (lanes 4, 5 and 7); 1.9 kb/1.9 kb, individuals homozygous for (lanes I and 2); and 2.7 kb/ (Dobson et al., 1989) .
Although the precise nature of the polymorphim we have identified is yet to be determined, another contngency is that it is a neutral polymorphism co-segregating with other progesterone receptor gene aberrations as yet undetected, as has been suggested in the case of an intron A polymorphism in the oestrogen receptor gene in breast cancer (Yaich et al., 1992) .
The demonstration of the tumour-suppressive properties of chromosome 11 in an ovarian cancer cell ine (Cao et al., 1993) as well as loss of beterozygosity in ovarian carcinoma (Foulkes et al., 1993) at the hPR gene locus 11q22-q23 (Rousseau-Merck et al., 1987; Mattei et al., 1988 ) raise the question of a possible tumour-suppressive role for the hPR.
The 1lq22-q24 locus contains a tumour-suppsor gene relevant to breast cancer (Stickland et al., 1992) and cervic carcinoma (Hampton et al., 1994) . Our data give credence to the possibility of a tumour-suppressive role for the hPR gene in ovarian carcnoma.
Consiring the hypothesis of Knudson (1971) that one defective copy of a tumour-suppressive gene is inherited and the other subject to a somatic mutation, the over-representation of the T1/I2 heterozygote in ovarian carcinoma patients suggests a possible scenario: that these individuals have inherited a defective copy of the hPR gene and that the other is subject to a somatic mutation. Long-term prospective studies will be required to monitor the incidnce of ovarian carcinoma in the control group, especially in those individuals with the T2FT2 genotype.
Whereas the frequency of the T2 alele is similar in the Irish ahd German case groups, the higher frequency of T2 in the Irish controls led to a smaler difference in T2 frequency between the Irish case and control groups, hence signnce could not be established in this population in this study. The fact that the distribution of the TaqI RFLP alleles approaches sigificnt deviation from that predicted by the Hardy-Weinberg equation (P<0.15) in the pooled controls will require further investigation.
To conclude, the current data show an association between a TaqI RFLP and incidence of ovarian carcinoma. This polymorphism is associated with ovarian cancer at a germlne leveL as opposed to the tumour level. Further work will characterise its role in the development of ovarian carcnoma.
